Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Short-term Investments (2016 - 2025)

Sangamo Therapeutics has reported Short-term Investments over the past 16 years, most recently at $912000.0 for Q3 2025.

  • Quarterly results put Short-term Investments at $912000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $912000.0 (changed N/A YoY), and the annual figure for FY2021 was $197.7 million, down 61.25%.
  • Short-term Investments for Q3 2025 was $912000.0 at Sangamo Therapeutics, roughly flat from $916000.0 in the prior quarter.
  • Over the last five years, Short-term Investments for SGMO hit a ceiling of $464.1 million in Q1 2021 and a floor of $912000.0 in Q3 2025.
  • Median Short-term Investments over the past 5 years was $197.7 million (2021), compared with a mean of $185.1 million.
  • Biggest five-year swings in Short-term Investments: soared 82.25% in 2021 and later plummeted 65.48% in 2023.
  • Sangamo Therapeutics' Short-term Investments stood at $197.7 million in 2021, then rose by 10.79% to $219.0 million in 2022, then plummeted by 65.48% to $75.6 million in 2023, then tumbled by 98.79% to $916000.0 in 2024, then fell by 0.44% to $912000.0 in 2025.
  • The last three reported values for Short-term Investments were $912000.0 (Q3 2025), $916000.0 (Q1 2024), and $75.6 million (Q3 2023) per Business Quant data.